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ABSTRACT
Umbilical cord blood hematopoietic stem cells coming from related or unrelated donors are an alternative
source of hematopoietic stem cells for patients undergoing transplantation for a wide variety of diseases. In the
unrelated donor transplant setting, shorter time to transplant, which is particularly relevant to patients
requiring urgent transplantation, and tolerance of 1–2 human leukocyte antigen mismatch, which increases the
chance of finding a suitable donor, are evident advantages over bone marrow transplantation. The speed of
engraftment is slower after cord blood transplantation but it is counterbalanced by a lower incidence of severe
graft-versus-host disease. Cell dose and human leukocyte antigen are major factors influencing outcome after
umbilical cord blood transplantation. Retrospective comparisons of clinical outcomes between unrelated cord
blood and unrelated bone transplantation in children and adults have shown similar results, showing the value
of this source of hematopoietic stem cell for transplantation. This review describes the recent clinical results
and discusses developing research strategies aimed at optimizing the results of cord blood transplantation.
© 2006 American Society for Blood and Marrow Transplantation
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Umbilical cord blood transplantation (UCBT) has
xtended the availability of allogeneic hematopoietic
tem cell transplantation (HSCT) to patients who
ould otherwise not be eligible for this curative ap-
roach. Since the ﬁrst successful UCBT from an
LA-identical sibling in a child with severe Fanconi
nemia reported by Gluckman et al. [1] in 1989, the
umber of UCBTs from siblings and unrelated do-
ors has increased dramatically, and we estimate that
ore than 5000 patients have undergone UCBT from
nrelated donors thus far. A recent survey of the
nternational Bone Marrow Transplant Registry
IBMTR) estimates that after 1998, 20% of stem cell
ransplantations performed in young patients (20
ears old) have been cord blood transplantations. In
apan, nowadays approximately 50% of HSCTs from
nrelated donors are being performed with cord blood
ells (T. Takahashi, Medical Director, Tokyo Cord
lood Bank, personal communication, 2005). The in-
entory of Netcord, the cooperative network of large (
4xperienced umbilical cord blood (UCB) banks, cur-
ently has more than 100 000 cryopreserved UCB
nits ready for clinical use, and a reasonably accurate
orldwide estimate would be 250 000 cord blood
nits. In comparison with other sources of allogeneic
SCT, UCB offers substantial logistic and clinical
dvantages, such as (1) signiﬁcantly faster availability
f banked cryopreserved UCB units, with patients
eceiving UCBTs a median of 25 to 36 days earlier
han those receiving bone marrow (BM) [2,3]; (2)
xpansion of the donor pool, because sufﬁciently large
CB units mismatched for 1 or 2 HLA-A, -B, and -DR
ntigens seem tolerated for survival; (3) a lower inci-
ence and severity of acute graft-versus-host disease
GVHD); (4) a lower risk of transmitting infections by
atent viruses, such as cytomegalovirus and Epstein-
arr virus; (5) reduced donor attrition, because cords
an likely be stored longer than an average living
onor remains available in a registry; and (6) easier
argeting of ethnic minorities and an increased pool of
are haplotypes [4]. The disadvantages of UCBT are
1) the low number of hematopoietic progenitor
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Related and Unrelated Cord Blood Transplantation
Bells and hematopoietic stem cells in UCB com-
ared with BM or mobilized peripheral blood (this
ranslates into an increased risk of graft failure and
elayed hematopoietic engraftment); (2) increased
esource utilization in hospitalization days and
lood and platelet transfusions; and (3) the impos-
ibility of using donor lymphocyte transfusion for
mmunotherapy.
LINICAL EXPERIENCE WITH UCBT
CBT from Related Donors
Related UCBT has been performed almost exclu-
ively in children [5]. In an update of the Eurocord
xperience with a median follow-up of 41 months
fter related UCBT for children, the survival estimate
t 3 years was 47%  5% in patients with malignan-
ies (n  96), 82%  7% in patients with BM failure
n  33), 100% in patients with hemoglobinopathies
n 52), of which 90% had a donor graft, and 70%
5% (n  10) in patients with inborn errors of me-
abolism or primary immunodeﬁciencies (Eurocord,
npublished data). For children with malignancies,
he 3-year overall survival was 71%  12% for those
n the early phase of the disease (ﬁrst complete remis-
ion of leukemia), 45%  7% for those in the inter-
ediate phase of the disease (second complete remis-
ion), and 24%  7% for those with an advanced
hase of the disease. A joint study by Eurocord and the
BMTR [6] compared the outcome of 113 children
able 1. Patient Disease and Transplant Characteristics and Outcomes
isease Status at Transplantation
Characteristic CR
edian age (y)
mmunophenotype (pre-B/B/T/null or biphenoptypic) 18%/
revious autologous transplantation, (n)
aryotype, (n)
Not available
Normal
Abnormal
Good and intermediate
Poor risk
edian time from diagnosis to UCBT (mo)
LA disparities (6/6), (n)
0
1
2
3-4
ucleated cell dose infused, median ( 107/kg)
BI-based regimen
edian follow-up, mo (range)
utcomes
Neutrophil recovery at day 60
Acute GVHD (II-IV) at day 100
Chronic GVHD at 2 y
TRM at day 100
Relapse at 2 y
LFS at 2 yR indicates complete remission; TBI, total body irradiation.
B&MTho received UCB from HLA-identical siblings with
hat of 2052 children who underwent HLA-identical
ibling BM transplantation (BMT). UCBT recipients
ad slower recovery of neutrophils and platelets and a
ower risk of acute and chronic GVHD. It is interest-
ng to note that relapse-related deaths, the mortality
ate at 100 days after transplantation, and overall sur-
ival were not signiﬁcantly different between the 2
roups [6]. Although longer follow-up is required,
hese ﬁndings suggest that in the HLA-identical sib-
ing setting, UCBT is as useful as BMT in children.
n the basis of these results, we recommend collect-
ng and freezing cord blood units in families in which
sibling child is affected with genetic or hematologic
iseases.
CBT from Unrelated Donors in Children
Multicenter [4-8], single-institution [3,9,10], and
onsortium [11,12] studies have shown that unrelated
onor UCBT in children was able to reconstitute
ematopoiesis and achieve sustained engraftment in
ost cases, was associated with a low incidence of
VHD, and did not result in a higher relapse risk.
lmost all pediatric series on UCBT from unrelated
onors have demonstrated the profound effect of cell
ose—measured as total nucleated cells, colony-form-
ng cells, and CD34 cells—on engraftment, adverse
ransplant-related events, and survival [5,7-9,13]. Al-
hough the prognostic importance of HLA disparity
Children with ALL Receiving an Unrelated UCBT According to
76) CR2 (n  136) Advanced Phase (n  111)
6 8
%/15% 17%/57%/17%/8% 10%/67%/12%/5%
) 5 (4%) 20 (18%)
) 35 (26%) 31 (28%)
) 53 (39%) 37 (33%)
) 48 (35%) 43 (39%)
) 32 (57%) 25 (58%)
) 16 (33%) 18 (42%)
28 33
) 14 (11%) 10 (10%)
) 61 (48%) 47 (47%)
) 47 (37%) 40 (39%)
) 4 (3%) 4 (4%)
3.7 3.4
) 107 (79%) 68 (61%)
0) 29 (3-93) 23 (3-96)
% 85  3% 65  5%
% 43  4% 36  5%
% 16  3% 12  3%
% 25  4% 34  5%
% 37  5% 48  7%
% 41  4% 24  4%of 323
1 (n 
4
47%/17
1 (1%
5 (7%
14 (18%
57 (75%
6 (11%
51 (89%
6
10 (14%
29 (42%
27 (39%
3 (4%
5.3
39 (51%
17 (3-6
75  5
46  6
15  4
22  5
34  8
42  635
w
a
w
b
a
r
t
l
p
t
f
T
i
t
t
3
c
(
s
e
o
m
r
p
U
ﬁ
(
T
t
w
e
i
X
s
a
o
H
d
1
o
w
n
0
u
b
c
i
A
a
w
G
(
(
d
w
(
t
s
p
i
w
d
G
G
t
A
6
a
W
(
n
n
c
t
d
a
U
D
B
m
p
b
d
u
B
i
r
a
i
p
m
(
n
p
w
w
a
t
g
c
w
U
s
t
G
N
f
d
V. Rocha and E. Gluckman
3as not clearly recognized in earlier series, it became
pparent in recent updates [8,9,13].
Recently, results of unrelated UCBT in children
ith speciﬁc diseases have been published in myelo-
lastic leukemia (AML) [7], Hurler syndrome [11],
nd Krabbe disease [12]. The Eurocord group has
ecently performed 2 studies (unpublished data) on
he outcomes of unrelated UCBT for childhood acute
ymphoblastic leukemia (ALL) and for children with
rimary immunodeﬁciencies. We have analyzed a to-
al of 323 children with ALL who received a UCBT
rom 1994 to 2004 in 24 countries, mostly in Europe.
he median age was 6.5 years, the median cell dose
nfused was 4.1  107/kg, and the median follow-up
ime was 22 months (range, 3-96 months). Overall,
he 2-year leukemia-free survival (LFS) was 36% 
%. In a multivariate analysis, only ﬁrst or second
omplete remission was associated with better LFS
hazard ratio [HR], 1.8; P  .0001). Therefore, a
eparate analysis was performed according to the dis-
ase status. Disease and patient characteristics and
utcomes are listed in Table 1. All children received
yeloablative conditioning regimens, and most (67%)
eceived cyclosporin A (CsA) and corticoids as GVHD
rophylaxis.
We have also analyzed the results of 82 unrelated
CBTs in children with severe primary immune de-
ciencies reported to the Eurocord by 40 centers
J. Ortega on behalf of Eurocord, unpublished data).
he median age was 0.9 years (range, 0-26 years), and
he median weight was 8 kg (range, 3-39 kg). There
ere 29 severe combined immunodeﬁciency dis-
ases, 19 Wiskott-Aldrich syndromes, and 34 other
mmunodeﬁciencies (chronic granulomatous disease,
-linked lymphoproliferative syndrome, Chediak-Higashi
yndrome, bare lymphocyte syndrome, Di George
nomaly, common variable immunodeﬁciency, and so
n). Considering HLA typing at the serologic level for
LA-A and -B and high-resolution DNA for -DRB1,
onor and recipient were matched in 16 cases and had
difference in 32 cases, 2 differences in 25, and 3 in
nly 2. The median number of nucleated cells infused
as 8.3  107/kg (range, 0.1-94), and the median
umber of CD34 cells was 3.4  105/kg (range,
.4-33). The conditioning regimen more commonly
sed was busulfan  cyclophosphamide (n  43) and
usulfan  others (n  17). Ten patients had no
onditioning; total body irradiation (TBI) was admin-
stered in 4 cases, and total lymphatic irradiation, in 2.
nti-T serotherapy (antithymocyte globulin [ATG],
ntilymphocytic globulin, or monoclonal antibody)
as given in 59 patients before transplantation.
VHD prophylaxis consisted of CsA plus steroids
n  42), CsA alone (n  16), CsA  methotrexate
n  9), and others (n  15). The cumulative inci-
ence of neutrophil recovery (500/mm3) at day 60
as 78%, and the incidence of platelet engraftment g
620,000/mm3) at day 180 was 63%. Nineteen pa-
ients did not engraft; 2 of them engrafted after a
econd UCBT. During the ﬁrst 3 months, 48% of
atients showed full and 20% showed mixed chimer-
sm; 8% had autologous reconstitution, and the data
ere not available in 24% (not reported, 13%; early
eath, 11%). The cumulative incidence of acute
VHD grade II to IV was 43%, and that of chronic
VHD was 13%. Data on immunologic reconstitu-
ion after transplantation was reported in 45 patients.
t 2 years, the estimated overall survival was 70% 
% for severe combined immunodeﬁciency disease
nd other immunodeﬁciencies and 67%  11% for
iskott-Aldrich syndrome. Twenty-six patients died
acute GVHD, n  8; infections, n  10; toxicity,
 6; rejection, n  1; and secondary malignancies,
 1).
In summary, these results show that UCBT can be
onsidered as a source of allogeneic stem cells for
ransplantation for children with genetic metabolic
iseases and malignant disorders who need an HSCT
nd who lack an HLA-identical sibling HSCT.
CBT Compared with BM from Unrelated
onors in Children
The comparison of the results of UCBT and
MT from unrelated donors in children is of para-
ount relevance, because for many patients the search
rocess will identify both UCB units and unrelated
one marrow (UBM) donors. Unfortunately, no ran-
omized clinical trial has been conducted to compare
nrelated cord blood transplantation and unrelated
MT. Three published studies—2 single-center stud-
es and a Eurocord registry series—have reported ret-
ospective analyses comparing outcomes after UCBT
nd unrelated bone marrow transplantation (UBMT)
n children [3,14,15]. The Eurocord group has com-
ared the outcomes of 99 children with acute leuke-
ia receiving an unrelated cord blood transplant
UCBT) with those of 442 children receiving either a
onmanipulated UBMT (n  262) or a T cell–de-
leted UBMT (T-UBMT) (n  180). Patients under-
ent transplantation from 1994 to 1998. Comparisons
ere performed after adjustment for patient, disease,
nd transplant variables. The major difference among
he 3 groups was the higher number in the UCBT
roup of HLA mismatches (deﬁned by serology for
lass I and molecular typing for DRB1). The donor
as HLA mismatched in 92% of UCBTs, in 18% of
BMTs, and in 43% of T-UBMT (P  .001). Other
igniﬁcant differences were observed in pretransplan-
ation disease characteristics, preparative regimens,
VHD prophylaxis, and the number of cells infused.
onadjusted estimates of 2-year survival and event-
ree survival rates for patients surviving more than 100
ays were 49% and 43%, respectively, in the UBMT
roup; 41% and 37% in the T-UBMT group; and
3
A
i
p
h
d
c
i
i
t
l
t
a
a
a
n
t
t
d
r
d
v
p
t
u
s
n
s
t
U
c
t
c
U
u
[
p
N
e
l
u
p
m
t
s
t
m
s
l
[
i
w
A
t
t
n
a
t
e
a
l
a
r
p
6
c
i
r
t
5
c
f
d
t
p
U
t
m
R
C
H
o
r
i
p
u
6
s
t
U
l
r
s
a
o
h
e
c
r
E
t
p
b
U
l
b
Related and Unrelated Cord Blood Transplantation
B5% and 31% in the cord blood transplant group.
fter adjustment, differences in outcomes appeared
n the ﬁrst 100 days after transplantation. Com-
ared with UBMT, UCBT recipients had delayed
ematopoietic recovery (P  .001), increased 100-
ay transplant-related mortality (P  .01), and de-
reased acute GVHD (P  .001). T-UBMT recip-
ents had decreased acute GVHD (P  .0001) and
ncreased relapse (P  .02). After day 100 after
ransplantation, the 3 groups achieved a similar re-
apse incidence. Chronic GVHD was decreased af-
er T-UBMT (P  .0001) and UCBT (P  .002),
nd there was a trend of higher overall mortality
fter T-UBMT (P  .07).
The Minnesota [14] and Montreal [3] groups have
nalyzed a smaller group of patients with malignant and
onmalignant disorders. As with the Eurocord analysis,
hey have shown that recipients of UCBT underwent
ransplantation in a shorter time compared with chil-
ren given a UBMT, that neutrophil and platelet
ecovery were delayed, that the acute GVHD inci-
ence was similar or decreased, and that overall sur-
ival was not signiﬁcantly different after UCBT com-
ared with UBMT.
These data gathered together strongly suggest
hat UCB is an acceptable alternative to matched
nrelated BM in children and support the start of a
imultaneous search for BM and UCB unrelated do-
ors. The ﬁnal selection of unrelated donor BM ver-
us UCB should be based on the urgency of the
ransplantation and the characteristics of the BM and
CB unrelated donor, such as cell dose and HLA
ompatibility. For children who require an urgent
ransplantation, UCB is advantageous for faster pro-
urement.
CBT from Unrelated Donors in Adults
A recent review focusing on the clinical results of
nrelated donor UCBT in adults has been published
16]. To date, more than 1400 UCBTs have been
erformed in adults with a unit coming from the
etcord organization (http://www.netcord.org); how-
ver, the available information in this setting is still
imited to small series of patients. Six major reports of
nrelated donor UCBT in adults [17-22] have been
ublished. As expected from retrospective studies and
ulticenter studies, the series were heterogeneous in
erms of recipients and disease-related characteristics,
uch as the type and status of the disease at transplan-
ation [17,21,22]. However, single centers report
ore homogenous series of patients and diseases with
tandard conditioning regimens and GVHD prophy-
axis [18-20]. For example, in the Japanese series
19,20], the analyses are from a single center, report-
ng patients with myelodysplastic syndrome or AML
ith a homogenous conditioning regimen (without w
B&MTTG) and with the use of methotrexate in combina-
ion with CsA as GVHD prophylaxis. Another impor-
ant difference is that in 4 of the 6 series, the median
umber of nucleated cells infused was 2  107/kg,
nd several patients received 1.5  107/kg—ﬁgures
hat are below recent recommendations [9,13]. How-
ver, in the Japanese series, very few patients received
cord blood cell dose inferior to 2107/kg. Granu-
ocyte colony-stimulating factor was commonly used
fter UCBT in all series. The myeloid engraftment
ate at 60 days has ranged from 80% to 100%, and the
robability of platelet engraftment at 180 days was
5% to 90%. The median time to achieve a neutrophil
ount 0.5  109/L varied from 22 to 32 days. The
ncidence of acute and chronic GVHD has widely
anged in adults undergoing unrelated UCBT, as has
ransplant-related mortality (TRM) at 100 days (0%-
4%) and disease-free survival (15%-76%). It is difﬁ-
ult to explain the reason for such differences, because
actors such as patient and cord blood graft selection,
isease and disease status, center effect, and period of
ransplantation may be involved. Moreover, studies of
rognostic factors with larger series of adults given a
CBT are still missing, and any attempt to explain
he different outcomes among these series is still pre-
ature.
esults of Unrelated Cord Blood Transplantations
ompared with Unrelated BMTs in Adults with
ematologic Malignancies
Three retrospective studies comparing the results
f UCBT and UBMT in adults [23-25] have been
ecently published. Investigators from a single center
n Japan have compared the outcomes of 113 adult
atients with hematologic malignancies who received
nrelated UBMT (n  45) or unrelated UCBT (n 
8). In this single-center analysis, the time from donor
earch to transplantation was signiﬁcantly shorter be-
ween UCBT recipients (median, 2 months) and
BMT recipients (11 months). Neutrophil and plate-
et recovery were delayed in UCBT recipients. UCBT
ecipients experienced a faster tapering of immuno-
uppressants after transplantation, and treatment of
cute GVHD with steroids was less frequent. More-
ver, no UCBT recipient died of GVHD, despite the
igh HLA mismatch. TRM was decreased, and dis-
ase-free survival was superior after UCBT when
ompared with UBMT. In this study, all but 4 patients
eceived a cord blood cell dose 2  107/kg [23].
urocord and the Acute Leukemia Working Party of
he European Group for Blood and Marrow Trans-
lantation have performed a retrospective registry-
ased comparative study of 98 UCBTs with 584
BMTs from unrelated donors in adults with acute
eukemia [24]. The transplantations were performed
etween 1998 and 2002. Recipients of cord blood
ere younger (median, 24.5 versus 32 years; P 
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3001), weighed less (median, 58 versus 68 kg; P 
001), and had more advanced disease at the time of
ransplantation (52% versus 33%; P  .001). All mar-
ow transplants were HLA matched, whereas 94% of
ord blood grafts were HLA incompatible (P  .001).
he median number of infused nucleated cells was
.23 108/kg for cord blood and 2.9 108/kg for BM
P  .001). Multivariate analysis demonstrated lower
isks of grade II to IV acute GVHD after UCBT
relative risk, 0.57; 95% conﬁdence interval, 0.37-
.87; P  .01), but neutrophil recovery was signiﬁ-
antly delayed (relative risk, 0.49; 95% conﬁdence
nterval, 0.41-0.58; P .001). Transplantation-related
ortality, relapse rate, chronic GVHD, and LFS were
ot signiﬁcantly different in the 2 groups. In another
egistry-based analysis, Laughlin et al. [25], on behalf
f IBMTR, found inferior outcomes for patients with
eukemia given a UCBT compared with an HLA-
atched UBMT; however, similar outcomes were
ound when UCBT was compared with 1-HLA-mis-
atched UBMT.
The results of these 3 comparative studies gath-
red together, despite their different results and al-
hough deﬁnitive conclusions will require larger and
omogenous series of patients with longer follow-up,
howed that UCBT is feasible in adults when a cord
lood unit contains a higher number of cells and
hould be considered an option as an allogeneic stem
ell source for patients lacking a HLA matched BM
onor. The results also show that despite increased
LA disparity, UCB from unrelated donors offers
romising results in adults with hematologic malig-
ancies, thus leading to the conclusion, as in children,
hat the donor search process for BM and UCB from
nrelated donors should be started simultaneously,
specially in patients with acute leukemia, for whom
he time factor is crucial.
esults of Unrelated Cord Blood Transplantations
ompared with Haploidentical Peripheral Blood
tem Cell Transplantation in Adults with
ematologic Malignancies
Haploidentical T cell–depleted peripheral
lood stem cell transplantation has emerged as an-
ther option for treating patients with high-risk
able 2. Unadjusted Outcomes after Haploidentical (Haplo) HSCT and
Variable
Cumulative Incidence
of Acute GVHD
Cumula
LL
Haplo (n  75) 8  3
UCBT (n  73) 26  5
P value .004
ML
Haplo (n  154) 5  5
UCBT (n  66) 23  5
P value <.0001 .44
8alignancies, mainly because of the lower risk of
elapse in patients with AML who receive a hap-
oidentical HSCT with killer immunoglobulin re-
eptor incompatibilities [26].
We have retrospectively analyzed data from
dult patients with ALL or AML who received ei-
her UCBT or haploidentical transplantation per-
ormed in European Group for Blood and Marrow
ransplantation centers from 1998 to 2002 (V.
ocha, unpublished Eurocord data). One hundred
orty-four patients had ALL (haploidentical, n 
5; UCBT, n  73), and 220 had de novo AML
haploidentical, n  154; UCBT, n  66). In the
LL group, UCBT patients were younger and re-
eived less TBI than haploidentical recipients. The
requency of patients with an advanced phase of
isease at transplantation was 45% in haploidentical
nd 51% in UCBT (P  .79). Cytogenetics and the
nterval from diagnosis to transplantation were not
tatistically different between groups. In the AML
roup, UCBT recipients were younger than hap-
oidentical recipients. Many patients underwent
ransplantation in an advanced phase of disease in
oth groups (58% of haploidentical recipients and
9% of the UCBT group), and other disease-related
actors were not signiﬁcantly different. Table 2 lists
he unadjusted outcomes after haploidentical
SCT and unrelated UCBT in adults according to
iagnosis.
After statistical adjustment for differences between
he 2 groups, in both analyses (ALL and AML),
CBT recipients had delayed neutrophil recovery
nd a higher incidence of acute GVHD (grade II-IV)
ompared with haploidentical recipients. In the AML
roup, relapse incidence, TRM, and LFS were not
tatistically different after UCBT or haploidentical;
owever, in the ALL group, LFS was superior and
elapse incidence decreased after UCBT compared
ith haploidentical transplantation.
In conclusion, in this registry-based retrospective
nalysis, UCBT and haploidentical showed similar
RM, relapse, and LFS for adults with AML. How-
ver, LFS was superior after UCBT for patients with
LL because of a decreased incidence of relapse.
in Adults with Acute Lymphoblastic or Myeloblastic Leukemia
cidence
I
Cumulative Incidence
of 2-y TRM
Kaplan-Meier
Estimate 2-y LFS
49  6 13  4
41  6 36  6
.55 .01
58  4 24  4
46  2 30  6UCBT
tive In
of 2y-R
38  5
23  4
.07
18  3
24  5.23 .39
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BNCIDENCE AND RISK FACTORS OF EARLY SEVERE
NFECTIONS AFTER UNRELATED CORD BLOOD
RANSPLANTATION
Delayed hematopoietic reconstitution has raised
oncern regarding the high incidence and type of
evere infections after unrelated UCBT. In fact, very
ew data are available to establish risk factors for se-
ere infections after UCBT in a large series of pa-
ients. The Eurocord group has retrospectively ana-
yzed 510 UCBTs performed from 1994 to 2002 in 55
urocord centers (unpublished data). The median age
as 6.9 years, and the median follow-up for survivors
as 36.6 months (range, 3-100 months); 396 (77%)
atients had hematologic malignancies, 65 (13%) had
nborn errors and severe primary immuno-deﬁcien-
ies, and 49 (10%) had BM failure. Conditioning was
BI based in 50% and associated with ATG/antilym-
hocytic globulin in 86%. CsA and glucocorticoids for
VHD prophylaxis were frequently used, and 269
atients (53%) received hematopoietic growth factor.
he donor was more frequently HLA disparate for
/6 (n  216; 43%) or 4/6 (n  204; 41%) HLA-A,
B, and -DR antigens. The median number of nucle-
ted cells and CD34 cells infused was 3.8  107/kg
nd 1.6  105/kg, respectively. In 95% of the cases,
atients underwent transplantation in a laminar air
ow room. Prophylaxis of infections varied among
enters. The incidence of ﬁrst infections was analyzed
y using competing risk analysis, and risk factors were
tudied by using cumulative hazard analysis of all in-
ectious episodes that occurred during 100 days after
CBT.
The cumulative incidences of neutrophil recovery,
cute GVHD (grade II-IV), and 100-day mortality
ere 75%, 38%, and 32% respectively. Cumulative
ncidences at day 100 of ﬁrst overall, bacterial, viral,
nd fungal infections were, respectively, 69%, 49%,
2%, and 10%. During the ﬁrst 100 days, 686 severe
nfections episodes were diagnosed in 352 patients. A
otal of 404 episodes were from a bacterial origin (276
ram positive, 124 gram negative, and 4 others), 189
ere severe viral infections or disease episodes (142
ytomegalovirus, 21 adenovirus, 12 Epstein-Barr vi-
us, 12 herpes simplex or human herpesvirus 6, and 2
aramyxovirus), 54 episodes were severe fungal infec-
ions (26 candidemia, 20 aspergillus, and 8 other), 5
pisodes were of toxoplasmosis, and 34 episodes were
ot classiﬁed. In a multivariate analysis, a shorter time
o engraftment decreased the cumulative hazard of
acterial infections (HR, 0.22; P  .0001). The fol-
owing factors decreased the cumulative hazard of
iral infections: negative cytomegalovirus serology
HR, 0.28; P  .001), 3/6 HLA disparate graft (HR,
.21; P .03), and a shorter time to engraftment (HR,
.40; P  .002). The following factors decreased the
umulative hazard of fungal infections: recipient’s m
B&MTge16 years (HR, 0.10; P .004), malignant disease
HR, 0.13; P  .03), a shorter time to engraftment
HR, 0.17; P  .02), and an absence of acute GVHD
rade III or IV (HR 0.24; P  .03). Considering all
ypes of infections, among the factors cited, the period
hen UCBT was performed (after 1998) was also
ssociated with a decreased hazard of severe infections
t day 100.
In summary, in this retrospective analysis, we ob-
erved that bacterial infections appeared early, fol-
owed by viral and fungal infections during the ﬁrst
00 days after UCBT. Delayed engraftment was fre-
uently associated with an increased risk of all types of
nfections. Approaches that will improve time to en-
raftment after UCBT might decrease the incidence
nd severity of early infections after UCBT.
TRATEGIES TO IMPROVE THE OUTCOMES OF CORD
LOOD TRANSPLANTATION
Many approaches have been proposed to improve
he results of unrelated cord blood transplantation.
hese approaches have been focusing on speeding
ime to hematopoietic recovery and reducing trans-
lant-related toxicity. The following strategies are
urrently being developed.
ccelerating Engraftment by Increasing the Cell
ose and Homing of UCB Units
. Optimization of the process of UCB collection,
establishment of high-quality UCB banks, and ex-
pansion of the pool of donors, which is particularly
relevant for ethnic and racial minorities.
. Ex vivo expansion of cord blood cells by using new
pharmacologic agents such as linear polyamine
copper chelator. Phase I clinical trials using ex-
panded cord blood cells with copper chelators have
already started in the United States and Europe.
. Transplantation of more than 1 cord blood unit.
Results with double cords, although preliminary,
support the safety of the procedure, with encour-
aging results [27].
. Cotransplantation of a UCB unit with highly pu-
riﬁed CD34 cells from haploidentical family do-
nors. Phase I/II clinical trials have been already
published, with interesting results.
. Cotransplantation of UCB cells with mesenchymal
stem cells from an allogeneic donor and intrabone
infusion of cord blood cells. These approaches may
improve engraftment. Phase I clinical trials have
just started in the United States and Europe.
hoosing the Best UCB Unit
It has been suggested that the cell dose and num-
er of HLA mismatches interact mutually on engraft-
ent and on other outcomes. Thus, a higher cell dose
39
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4n the graft could partially overcome the negative
ffect of HLA for each level of HLA disparity; how-
ver, this hypothesis has not been demonstrated.
owever, on the basis of previous data [8,9] and Eu-
ocord data [13], we recommend a cord blood graft
ith no more than 2 HLA disparities and with nucle-
ted cells 2.5  107/kg at cryopreservation. In a
ecent collaborative study between the Düsseldorf
ord Blood Bank and the Eurocord-Netcord registry,
e have tried to analyze the effect of HLA high-
esolution typing for class I and II on outcomes after
CBT. We studied 122 patient/cord blood donor
ombinations by using high-resolution DNA typing
or both HLA class I (HLA-A, -B, and -C) and class II
HLA-DRB1 and -DQB1) loci (G. Koegler, unpub-
ished data). The analysis showed a large number of
LA disparities between recipient and donor (up to
/10 mismatches on the allelic typing level); however,
e were not able to ﬁnd any association of the number
nd type of HLA incompatibilities with engraftment,
cute GVHD, transplant-related mortality, or survival
y using high-resolution tying. This ﬁnding is prob-
bly due to the high number of HLA incompatibilities
ncountered in a relatively small and heterogeneous
roup of unrelated UCBT recipients.
educing Conditioning-Related Mortality
Encouraging results regarding engraftment and
RM have recently been reported with the use of
educed-intensity conditioning regimens [28]. In the
argest experience to date, investigators from the Uni-
ersity of Minnesota have reported the preliminary
esults of UCBT from mismatched unrelated donors
fter nonmyeloablative conditioning in 43 adult pa-
ients (median age, 49.5 years) with advanced or high-
isk hematologic malignancies. In this series, some
atients received 2 cord blood units, and 2 there were
ypes of nonmyeloablative conditioning regimens: ﬂu-
arabine 200 mg/m2, busulfan 8 mg/kg, and TBI 200
Gy (Flu/Bu/TBI) for 21 patients and ﬂudarabine 200
g/m2, cyclophosphamide 50 mg/kg, and TBI 200
Gy (Flu/Cy/TBI) for the remaining cases. All pa-
ients received CsA and mycophenolate mofetil as
VHD prophylaxis. The median time to neutrophil
ecovery was 26 days (range, 12-30 days), with a cu-
ulative incidence of 76% for the Flu/Bu/TBI recip-
ents, and was only 9.5 days (range, 5-28 days), with a
umulative incidence of 94%, for the Flu/Cy/TBI
ecipients. The cumulative incidence of acute GVHD
rade II to IV and III/IV was 44% and 9%, respec-
ively. TRM at day 100 was 48% for Bu/Flu/TBI
ecipients and 28% for Flu/Cy/TBI recipients. Causes
f death during the ﬁrst 100 days were predominantly
rgan failure and infections. Disease-free survival at 1
ear for these high-risk patients was 24% for Flu/Bu/
BI recipients and 41% for Flu/Cy/TBI recipients. B
0espite these encouraging results, more experience
nd a longer follow-up are needed.
mproving Immune Reconstitution
Immune recovery after UCBT is an area of great
nterest and concern because of the low number and
mmaturity of UCB lymphocytes, as well as the degree
f HLA mismatching. Despite those facts, several
tudies have shown that immune reconstitution in
hildren undergoing UCBT is not delayed compared
ith BMT in terms of the number of T- and B-
ymphocyte and natural killer lymphocyte subsets and
f the T-cell repertoire diversity and thymic function
nd recovery of speciﬁc immune response toward vi-
uses and fungi. In contrast, central T-cell recovery
nd lymphocyte recovery are delayed after UCBT in
dults compared with children, especially in the pres-
nce of GVHD.
ONCLUSIONS
UCB has emerged as an appealing alternative
ource of hematopoietic stem cells for transplantation.
lthough many issues remain uncertain and greater
xperience will be required to clearly determine the
elative merits of UCBT compared with BMT, all
vailable data suggest that unrelated donor UCBT
hould be considered an acceptable option in children
nd adults with hematologic and nonhematologic ma-
ignancies for whom an HLA-matched unrelated BM
onor is not readily available. A shorter time to trans-
lantation and an improved chance of ﬁnding a suit-
ble graft are evident advantages of unrelated donor
CBT over unrelated donor BMT [2,3]. This is par-
icularly relevant to patients who require urgent trans-
lantation. Increasing the available pool of UCB units
ould increase the probability of ﬁnding one suitable
ith more cells and fewer HLA disparities and seems
o be a feasible way of improving the results of
CBTs. This simple approach probably offers much
ore room for improvement regarding the outcome
han expanding the current pool of unrelated BM
onors. Hopefully, current research approaches and
reater experience of transplant centers with UCBT
ill improve outcomes and will provide successful
herapy to more patients who need an allogeneic
SCT.
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